Stockreport

Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024

Vir Biotechnology, Inc.  (VIR) 
PDF SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the EASL Congress has changed the Company’s Phase 2 SOLSTICE hepatitis delta pr [Read more]